Induction chemo-immunotherapy

DRUG4 trials

Sponsors

Sun Yat-sen University, NYU Langone Health, RenJi Hospital

Conditions

Esophageal Squamous Cell CancerEsophageal Squamous Cell CarcinomaNon-small Cell Lung CancerOropharyngeal Squamous Cell Carcinoma

Phase 1

Fraction Dose Escalation of Split-course Hypofractionated Concurrent Chemoradiotherapy Following Induction Chemo-immunotherapy in Unresectable Locally Advanced Esophageal Squamous Carcinoma: a Phase I Study.

Active, not recruitingNCT06020885

Sun Yat-sen UniversityEsophageal Squamous Cell Carcinoma

Start: 2023-08-31End: 2025-10-30Target: 18Updated: 2025-07-21

Lattice-Based Radiotherapy and Chemoimmunotherapy for Oropharyngeal Squamous Cell Carcinoma

Not yet recruitingNCT07428148

NYU Langone HealthOropharyngeal Squamous Cell Carcinoma

Start: 2026-05-01End: 2033-05-01Target: 60Updated: 2026-02-23

Phase 2

The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC

CompletedNCT06139419

Sun Yat-sen UniversityNon-small Cell Lung Cancer

Start: 2023-07-25End: 2026-06-30Updated: 2026-08-03

Unknown Phase

Retlirafusp Alfa Combined With Chemoradiotherapy in Unresectable ESCC

Not yet recruitingNCT07769866

RenJi HospitalEsophageal Squamous Cell Cancer

Start: 2026-09-01End: 2030-06-30Target: 68Updated: 2026-08-18